Trade Names:E. S. P.- Granules for oral suspension Erythromycin ethylsuccinate (equivalent to 200 mg erythromycin activity) and sulfisoxazole acetyl (equivalent to 600 mg sulfisoxazole) per 5 mL when reconstituted
Erythromycin suppresses bacterial protein synthesis; sulfonamides interfere with bacterial folic acid synthesis.
C max is 0.3 to 2 mcg/mL. T max is 1.6 h.
Largely bound to plasma proteins. Diffuses into most body fluids. Passage across the blood-brain barrier increases in meningitis. Crosses the placenta and is excreted in breast milk.
Metabolized in the liver by demethylation.
Mostly excreted in the bile; less than 5% recovered in the active form in the urine.
Treatment of acute otitis media in children caused by susceptible strains of Haemophilus influenzae .
Hypersensitivity to chemically related drugs (eg, sulfonylureas, thiazide and loop diuretics, carbonic anhydrase inhibitors, sunscreens containing PABA, local anesthetics) or salicylates; patients taking terfenadine or astemizole; porphyria; use in infants younger than 20 mo of age, pregnant women at term and women breast-feeding infants younger than 2 mo of age.
PO 50 mg/kg/day erythromycin and 150 mg/kg/day (max 6 g/day) sulfisoxazole in equally divided doses 4 times daily for 10 days.
Refrigerate after opening. Discard unused portion after 14 days.
May increase anticoagulant effects.Antihistamines, non-sedating (eg, astemizole, terfenadine)
Erythromycin significantly alters metabolism of terfenadine. Rare cases of serious CV events including death have been reported.Astemizole, bromocriptine, carbamazepine, disopyramide, hexobarbital, methylprednisolone, phenytoin
May cause decreased metabolism and increased concentrations of these drugs.Cyclosporine
Erythromycin may interfere with metabolism while sulfonamides may decrease cyclosporine levels; both increase risk of nephrotoxicity.Digoxin
May increase digoxin levels.Lovastatin
Severe myopathy or rhabdomyolysis may occur.Methotrexate
Sulfonamides can displace methotrexate from protein-binding sites and increase free methotrexate levels.Sulfonylureas
Sulfisoxazole may potentiate hypoglycemic effects.Theophyllines
May increase theophylline plasma concentrations.Thiopental
May enhance anesthetic effects of thiopental.
Sulfisoxazole may produce false-positive results.Urinary glucose test
Sulfonamides may produce false-positive results when performed by Benedict's method.Urobilistix test
Sulfisoxazole may interfere with test results.
Headache; peripheral neuropathy; dizziness; psychosis; hallucinations; depression; convulsions.
Urticaria; skin eruptions; pruritus; photosensitivity; anaphylaxis; erythema multiforme; toxic epidermal necrolysis; exfoliative dermatitis; angioedema; arteritis; vasculitis.
Hearing loss (associated with high doses erythromycin and renal insufficiency).
Nausea; vomiting; abdominal pain/cramping; diarrhea; anorexia.
Crystalluria; hematuria; increased BUN and creatinine; nephritis; toxic nephrosis with oliguria.
Hepatic dysfunction; abnormal LFT results; pseudomembranous colitis; GI hemorrhage; pancreatitis.
Leukopenia; agranulocytosis; aplastic anemia; thrombocytopenia; hemolytic anemia; purpura; eosinophilia; clotting disorders; methemoglobinemia.
Fever; chills; arthralgias; myalgias; periarteritis nodosum; systemic lupus erythematosus; serum sickness.
MonitorResponse to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not improve or appears to worsen.
Category C .
Both erythromycin and sulfisoxazole are excreted in breast milk.
Do not expose children younger than 2 mo of age (directly or through breast milk) to sulfonamides because of risk of kernicterus.
Use drug with caution in patients with renal function impairment. Hepatotoxicity has been associated with erythromycin.
Use drug with caution in patients with hepatic function impairment. Hepatotoxicity has been associated with erythromycin.
May aggravate weakness in patients with myasthenia gravis. Use drug with caution in patients with severe allergies or bronchial asthma. Dose-related hemolytic anemia may occur in patients with G-6-PD deficiency.
Prolonged use may result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Rare fatalities from severe reactions associated with hypersensitivity, agranulocytosis, aplastic anemia, blood dyscrasias, renal and hepatic damage, irreversible neuromuscular and CNS changes, and fibrosing alveolitis have been reported with sulfonamides.
May occur, especially in patients with renal or hepatic insufficiency and elderly patients and with administration of large doses.
Consider possibility in patients with diarrhea.
Nausea, vomiting, diarrhea, hearing loss, vertigo, dizziness, headache, drowsiness, unconsciousness, toxic fever, acidosis, hemolytic anemia.
Copyright © 2009 Wolters Kluwer Health.